Abstract
Background
Healthcare systems have increasingly limited and stretched budgets. Clinicians have a key role in budget allocation. Awareness of the costs of high-use clinical items is important.
Aims
Assess awareness of the cost of commonly utilised clinical items amongst Irish Ophthalmologists
Methods
Irish ophthalmologists were contacted and asked to fill out an anonymous survey. We assessed knowledge of hospital costs of surgical materials, medications and anti VEGF drugs as well as retail pharmacy costs of commonly prescribed medications. The cost of items to the hospital was recorded from pharmacy and ward order receipts from a single university hospital. The costs of items to the patient were calculated by taking an average of 3 prices charged by local retail pharmacies. For each estimate we calculated the absolute error from the true price. We calculated the mean absolute errors (MAE) and percentage errors (MAPE) across the different groups.
Results
We received responses from 47 participants (15 Senior House Officers, 11 Registrars, 21 Consultant/Community Ophthalmologists). Despite 70% of respondents agreeing that the cost of an item should have a major role in its use, the average estimate was 124% inaccurate. Less than 50% of responses were within 50% of the true cost of the item. Self-perceived knowledge was acknowledged to be limited or very limited in 73% of responses.
Conclusions
We demonstrate variable and limited levels of cost awareness. Seniority and better self-perceived knowledge were not found to be associated with better estimate accuracy.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Background
Healthcare expenditure grows year on year. The estimated 2020 health expenditure in Ireland is €20.3 billion [1]. Clinicians are responsible for 70% of budget expenditure in healthcare [2]. Pharmaceutical expenditure ranges from 8.5% to 29.6% of health spending within Organisation for Economic Co-operation and Development countries and is increasing faster than other areas of health-care spending in almost all countries [3].
High-value, cost-conscious care refers to care that aims to assess the benefits, harms, and costs of interventions and consequently to provide care that adds value [4]. Given the fact that we all work within a limited budget, the value of a drug or item cannot be appreciated without knowing the cost. Despite this, many clinicians receive little or no formal training on the costs of the materials they use and the drugs they prescribe. To manage budgets effectively, clinicians must have a reasonable understanding of the costs associated with their practice.
In addition to costs to health systems and departments, it is important to understand how much different drugs cost patients. In some cases, patients continue to purchase drugs at high personal cost when suitable alternatives exist [5]. In others, drugs are discontinued unbeknownst to the doctor due to budgetary constraints [6, 7].
The aim of this study was to gauge the level of knowledge possessed by Irish ophthalmologists about the costs of commonly used drugs and clinical equipment. We were also interested to see if there was an association between seniority and estimate accuracy.
Methods
All currently practicing Irish ophthalmologists were contacted via email. Respondents were asked for estimates, to the nearest Euro, of the cost of a list of common clinical items. We divided the items into 4 categories – cost of: medications to the hospital (9 items), surgical materials to the hospital (15 items), anti-VEGF medications to the hospital (3 items) and medications to the patient (8 items). Participants were asked to record their level of training as Senior House Officer [SHO], Registrar/ Specialist Registrar [SPR] and Consultant/Community Ophthalmologist (COP).
The cost of each item was per unit (i.e. per bottle of medication, per pair of gloves etc.) and this was stated clearly in each question. Where different volumes are in common use, a specific volume was indicated. We recorded the hospital costs of items from ward and pharmacy receipts. We calculated average costs to the patient by taking an average from three local retail pharmacies.
In our statistical analysis we looked at the 4 categories separately and overall. We also looked at each level of seniority separately. Naturally, some estimates were above and some below the true cost. This limits the usefulness of a simple mean estimate per item. The primary measure of the accuracy of estimates that we used was the mean absolute error (MAE). The absolute error of each estimate per item was calculated:
xi is the estimate; x is the true value.
The MAE was then calculated per item. The MAE expressed as percentages of the true cost of each is the mean absolute percentage error (MAPE). This facilitates comparison between items of different prices. Standard deviation calculations were also performed for each item.
Respondents also answered questions relating to their self-perceived knowledge of cost of common medications/items and the level of influence the price of an item should have on its use in clinical practice.
Results
There were 47 respondents to the study (21 Consultant/[COP, 11 SPRs/Registrars and 15 SHOs). Just 4% of respondents reported their self-perceived knowledge as very good or good. Limited or very limited knowledge was reported by 47%. Consultants/COPs were more likely to report good or average knowledge than SPR/Reg and SHO groups (43%, 9% and 0% respectively).
The majority of respondents agreed that the price of items should factor into their use - 70% responding this should be the case always or as much as patient safety/clinical efficacy allows. Despite this, just 50% of estimates were within 50% of the true cost (Fig. 1). The mean average percentage errors are categorized in Fig. 2.
Estimate accuracy varied widely across different categories of items. The MAPE was highest in the perioperative material section followed by the hospital medications, anti-VEGF drugs and retail pharmacy medications (243, 124, 75 and 53% respectively).
When the respondents were broken down into 3 groups based on seniority, the Consultant/COP group’s estimates were more accurate but there was no statistical difference between the groups (Table 1, P=0.47; Kruskal Wallis). They had the lowest MAPE in 2 of the four groups (hospital medications and perioperative materials) and the lowest overall MAPE.
Before providing estimates, responders were asked to rate their self-perceived knowledge. No clinicians rated their knowledge as very good, 2 rated it as good with average, limited and very limited selected by 8, 18 and 9 respectively (NR from 10). Self-perceived knowledge was not found to predict better estimates (Table 2, P=0.18, Kruskal Wallis).
Discussion
It is clear from the results that the cost of many items are poorly understood by Irish ophthalmologists. This finding has been demonstrated by other studies across a variety of healthcare specialities [8,9,10,11]. Allan et al performed a systematic review of 24 studies and found that clinicians consistently overestimated the cost of inexpensive products and underestimated the cost of expensive ones [12]. Doctors estimates were within 25% of the true cost less than one third of the time. We noted similar findings in our cohort (27%).
The hospital cost responses (medications, surgical materials and anti-VEGF drugs) highlighted a significant knowledge gap with less than one third of responses being accurate to +/- 25%. For high cost and frequent use items in particular, this lack of awareness is not conducive with efficient use of a departmental budget. The anti-VEGF medications are a good example of similar drugs with very large price differences. There are a small number of conditions that may respond better to the more expensive Aflibercept and Ranabizumab, but the generic drug Avastin has been shown in multiple trials to be non-inferior in treatment of AMD and retinal vein occlusions associated with macular oedema [13,14,15]. In a situation where the non-inferiority of a more cost effective option has been proven, it should be first line. Many respondents to our survey were unaware of the extent of the price difference between these agents.
It is alarming that neither seniority nor self-perceived knowledge was associated with more accurate estimates (Tables 1 and 2). The Consultant/COP group had the lowest average error but this difference did not meet statistical significance. Some Community Ophthalmologists (COPs) may have a limited understanding of surgical costs which may explain some of the outliers in this section. That being said, there were poor estimates across all groups, including those who predicted accurate responses. Senior ophthalmologists are department level decision makers and should set the standard for costs awareness amongst other staff.
Clinicians are trained to work up patients, make clinical decisions and formulate treatment plans but these decisions dictate the finances of patients and the health sector as a whole. The dual roles of clinicians and managers are inseparable and increasingly consequential. The judicious use of resources is ultimately the clinicians responsibility.
Improving cost-consciousness amongst doctors is a challenge. Each treatment decision has multiple factors influencing the final outcome. However, with ever increasing healthcare expenditure it is a must. We firmly believe that medical training should include the basics of healthcare economics. Subspecialties of all disciplines should educate their trainees and themselves about the costs of the tests they order and treatments they initiate.
References
Parlimentary Budget Office (2020) https://data.oireachtas.ie/ie/oireachtas/parliamentaryBudgetOffice/2020/2020-04-17_revised-estimates-2020-health-vote-38_en.pdf . Accessed 5/10/21
Hillman A, Nash D, Kissick W et al (1986) Managing the medical-industrial machine. NEMJ 315:511–13
OECD Health Division (2006) OECD Health Data Available: http://www.oecd.org/dataoecd/20/51/37622205.xls
Stammen LA, Stalmeijer RE, Paternotte E et al (2015) Training Physicians to Provide High-Value, Cost-Conscious Care: A Systematic Review. JAMA. 314(22):2384–2400. https://doi.org/10.1001/jama.2015.16353
Cox ER, Jernigan C, Coons SJ et al (2001) Medicare beneficiaries' management of capped prescription benefits. Med Care 39:296–301
Spence MM, Hui R, Chan J (2006) Cost reduction strategies used by elderly patients with chronic obstructive pulmonary disease to cope with a generic-only pharmacy benefit. J Manag Care Pharm. 12:377–382
Piette JD, Heisler M, Wagner TH (2004) Cost-related medication underuse: Do patients with chronic illnesses tell their doctors? Arch Intern Med. 164:1749–1755
Nethathe GD, Tshukutsoan S, Denny KJ (2017) Cost awareness among healthcare professionals at a south african hospital: A cross-sectional survey. South African Med J 107(11):1010. https://doi.org/10.7196/samj.2017.v107i11.12513
Barclay LP, Hatton RC, Doering PL et al (1995) Physicians' perceptions and knowledge of drug costs: results of a survey. Formulary 30:268-70, 272, 277-9
Schilling UM (2019) Cost awareness among Swedish physicians working at the emergency department. Eur J Emerg Med 16(3):131–134. https://doi.org/10.1097/MEJ.0b013e32831cf605
Bade K, Hoogerbrug J (2015) Awareness of surgical costs: A multicenter cross-sectional survey. J Surg Educ 2(1):23–27
Allan GM, Lexchin J, Wiebe NO (2007) Physician awareness of drug cost: a systematic review. PLoS Med 4(9):e283. https://doi.org/10.1371/journal.pmed.0040283. PMID: 17896856; PMCID: PMC1989748
Chakravarthy U, Harding SP, Rogers CA et al (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382(9900):1258-67. https://doi.org/10.1016/S0140-6736(13)61501-9. Epub 2013 Jul 19. PMID: 23870813
Schauwvlieghe AM, Dijkman G, Hooymans JM et al (2016) Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study. PLoS One 11(5):e0153052. https://doi.org/10.1371/journal.pone.0153052. PMID: 27203434; PMCID: PMC4874598
Scott IU, VanVeldhuisen PC, Ip MS et al, SCORE2 Investigator Group (2017) Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial. JAMA 317(20):2072-2087. https://doi.org/10.1001/jama.2017.4568. PMID: 28492910; PMCID: PMC5710547
Funding
Open Access funding provided by the IReL Consortium.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interests
The author declares no conflicts of interest regarding this publication.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Power, B. Cost awareness amongst irish ophthalmologists. Ir J Med Sci 192, 3147–3150 (2023). https://doi.org/10.1007/s11845-023-03332-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-023-03332-7